These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33852619)

  • 1. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
    Chaves-Torres NM; Fadul S; Patiño J; Netto E
    PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
    Woldeyohannes D; Assefa T; Aman R; Tekalegn Y; Hailemariam Z
    PLoS One; 2019; 14(10):e0224025. PubMed ID: 31665154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistant tuberculosis in Saudi Arabia: an analysis of surveillance data 2014-2015.
    Al Ammari M; Al Turaiki A; Al Essa M; Kashkary AM; Eltigani SA; Ahmed AE
    Antimicrob Resist Infect Control; 2018; 7():12. PubMed ID: 29387346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
    Habimana DS; Ngabonziza JCS; Migambi P; Mucyo-Habimana Y; Mutembayire G; Byukusenge F; Habiyambere I; Remera E; Mugwaneza P; Mwikarago IE; Mazarati JB; Turate I; Nsanzimana S; Decroo T; de Jong CB
    Am J Trop Med Hyg; 2021 May; 105(1):47-53. PubMed ID: 33999845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis.
    Abraham Y; Assefa DG; Hailemariam T; Gebrie D; Debela DT; Geleta ST; Tesfaye D; Joseph M; Manyazewal T
    BMC Infect Dis; 2024 Oct; 24(1):1087. PubMed ID: 39354416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affecting Factors Unfavorable Treatment Outcomes of Rifampicin-resistant/Multidrug-resistant Tuberculosis Patients Treated with Long-term Regimen.
    Babalik A; Balikçi A; Turkar A; Teke NH; Demir FK; Yavuz S; Koç EN; Gündüz S; Ergeç B; Alagöz HC; Sarioğlu E; Kiliçaslan Z
    Int J Mycobacteriol; 2024 Jul; 13(3):265-274. PubMed ID: 39277888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with unfavourable treatment outcomes among people with rifampicin-resistant tuberculosis in Armenia, 2014-2017.
    Khachatryan L; Grigoryan R; Dadu A; Kumar AMV; Akopyan K; Dumchev K; Harutyunyan H; Matteelli A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.
    Kamara RF; Saunders MJ; Sahr F; Losa-Garcia JE; Foray L; Davies G; Wingfield T
    Lancet Glob Health; 2022 Apr; 10(4):e543-e554. PubMed ID: 35303463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan.
    Khan A; Khan AH; Ahmad N; Ghafoor A
    J Infect Public Health; 2024 Sep; 17(9):102522. PubMed ID: 39173557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with unfavorable treatment outcomes among multidrug-resistant tuberculosis patients, Sierra Leone: a cross-sectional secondary data analysis.
    Koroma JA; Elduma AH; Sesay U; Gebru GN
    BMC Infect Dis; 2024 Jun; 24(1):579. PubMed ID: 38862873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
    Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C
    Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort study.
    Diktanas S; Korotych O; Sereda Y; Gozalov O; Rubcova O; Achar J
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.